ClinicalTrials.gg
RecruitingNCT07561892AMLUpdated May 1, 2026

Study of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3).

A Phase 4 interventional study of daunomycin/Idarubicin+ Silybinin and daunomycin/Idarubicin in Acute Myeloid Leukemia, Newly Diagnosed and Chemotherapy Effect, sponsored by Fujian Medical University Union Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by Fujian Medical University Union Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 2 years 10 months after the study started (first participant enrolled Apr 2022, registered Feb 2025).
  • Started Apr 2022; still recruiting 4 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies testing daunorubicin in Leukemia, Myeloid, Acute — 11 open to participants now, 16 under way, 4 of them phase 3. Daunorubicin · Leukemia, Myeloid, Acute.

Planned enrollment
25th of 48
100 · median 111
Started
2022
with 1 other
Phase 4
Only one
of the 50
Primary completion
2026-12
later than 3 of 15 live
Registered
46th of 50
by date
Lead sponsor
1 of 50
Fujian Medical University Union Hospital

Among the 50 studies testing daunorubicin in Leukemia, Myeloid, Acute, this one is the 25th largest by planned enrollment of the 48 interventional ones that give a count, is one of 2 that started in 2022, is the only one in phase 4, reaches primary completion later than 3 of the 15 other live ones, and was the 46th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

11 of the 50 studies testing daunorubicin in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About daunorubicin

Daunorubicin: first FDA approval 1979 (CERUBIDINE), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing daunorubicin in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

Silibinin is the major active component of silymarin, a commonly used hepatoprotective agent. It stabilizes hepatocyte membranes, preserves cellular integrity, and accelerates DNA synthesis in liver cells. Clinically, it is widely used in the treatment of chronic persistent hepatitis, chronic active hepatitis, early-stage liver cirrhosis, and hepatotoxicity. Moreover, it has been reported to inhibit the growth and differentiation of various cancer cells, including hepatocellular carcinoma, prostate cancer, breast cancer, and cervical cancer.

Based on these preclinical findings, we aim to evaluate the efficacy and safety of combining silybinin with the standard first-line idarubicin/daunorubicin-based regimen in the treatment of newly diagnosed acute leukemia(non-M3)in a clinical setting.

03

Conditions studied

  • Acute Myeloid Leukemia
  • Newly Diagnosed
  • Chemotherapy Effect

Keywords

  • AML
  • newly diagnosed
  • Silybin
  • daunorubicin
  • Idarubicin
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Newly diagnosed acute leukemia(non-M3)confirmed according to the 2018 WHO classification criteria for the diagnosis and classification of acute leukemia;
  2. Suitable for standard chemotherapy regimens containing idarubicin/daunorubicin;
  3. Patients with an expected survival time of at least 3 months as determined by the investigator;
  4. Voluntarily agree to participate in this study and sign the form.

Exclusion criteria

Exclusion Criteria:

  1. History of other malignant tumors concurrently or previously diagnosed not under control;
  2. Participation in other clinical trials within one month prior to screening;
  3. Presence of uncontrolled cerebrovascular diseases, coagulation disorders, connective tissue diseases, or other such conditions;
  4. Other uncontrolled diseases that the investigator considers inappropriate for inclusion;
  5. Patients with psychiatric disorders or other known or suspected inability to fully comply with the study protocol;
  6. Pregnant or breastfeeding women;
  7. History of liver cirrhosis, or current active liver disease or biliary disease;
  8. -positive individuals;
  9. Any other conditions that, in the investigator's judgment, may prevent the subject from completing the study or pose significant risk to the subject.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    daunomycin/ Idarubicin + Silybinin treatment

    The chmotherapy protocol includes daunomycin 60mg/m2/d or Idarubicin 10mg/m2/d for 3 days, at the same time, Silybin 200mg tid is administrated.

    Drug: daunomycin/Idarubicin+ Silybinin

  • Experimental
    daunomycin/Idarubicin treatment

    The chmotherapy protocol includes daunomycin 60mg/m2/d or Idarubicin 10mg/m2/d for 3 days

    Drug: daunomycin/Idarubicin

Interventions

06

What researchers measure

Primary outcomes

  1. overall remission rate (ORR)

    subjects achieving complete remission (CR) or partial remission (PR) at the end of cycle 1and cycle 2(each cycle is 1 month)

    Time frame: At the end of Cycle 1 and Cycle 12 (each cycle is 1 month)

  2. overall survival (OS)

    subjects survival after treatment are finished

    Time frame: 1-year

Secondary outcomes

  1. Time to Response(TTR)

    The time from initiation of the study treatment to the first documentation of CR or PR.

    Time frame: 1-2months(1-2 courses)

  2. Duratin of Response(DOR)

    The time from first documentation of CR to the first documented disease progression or death, whichever occurs first

    Time frame: 1-year

  3. Progression-Free Survival(PFS)

    The time interval from the start of the study treatment to the first documentation of disease progression or death from any cause,whichever occurs first

    Time frame: 1-year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2022 (actual). Primary completion is estimated for Dec 2026, 56 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2025
First posted
May 1, 2026
StartActual
Apr 1, 2022
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07561892
Responsible party
HuangMeiJuan (Chief Physician, Fujian Medical University Union Hospital) — Principal investigator
First posted
May 1, 2026
Start date
Apr 1, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 1, 2026

Study contacts

Meijuan Huang
Contact
huangmj@fjmu.edu.cn
13365910912
Shuxia Zhang, MD
Contact
zhangshuxia235@163.com
86-18006908855
Yuanzhong Chen, MD
study director · Fujian Institute of Haematology, Fujian Medical University Union Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Daunorubicin · Idarubicin · Silybin

Start the discussion